(Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2021 conference call on Wednesday, November 10, at 7:30 a.m. Surmodics Reports Third Quarter Fiscal 2022 ResultsĮDEN PRAIRIE, Minn.EDEN PRAIRIE, Minn.-( BUSINESS WIRE)-Surmodics, Inc. Do the numbers hold clues to what lies ahead for the stock? SurModics (SRDX) delivered earnings and revenue surprises of 12.82% and 2.46%, respectively, for the quarter ended June 2022. SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates However, the company expects softer demand for its products and services in the second half of 2022. Product sales primarily drive Surmodics' (SRDX) third-quarter top-line growth. Surmodics (SRDX) Beats on Q3 Earnings, Revises FY22 View Surmodics to Present at Upcoming Gilmartin Emerging Growth Company Showcase Wednesday, August 31, 2022ĮDEN PRAIRIE, Minn., August 23, 2022-Surmodics to Present at Upcoming Gilmartin Emerging Growth Company Showcase Wednesday, August 31, 2022. Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business. 3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now The table below shows SRDX's key quality metrics over time.īelow are the latest news stories about SURMODICS INC that investors may wish to consider to help them evaluate SRDX as an investment opportunity. MMSI, POAI, and OSUR are the stocks whose asset turnover ratios are most correlated with SRDX.SRDX's asset turnover comes in at 0.604 - ranking 71st of 186 Medical Equipment stocks.SRDX has a Quality Grade of B, ranking ahead of 94.57% of graded US stocks.Here are some key insights as we drill into the specifics of these quality attributes. SRDX's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. The table below shows SRDX's growth in key financial areas (numbers in millions of US dollars). Over the past 33 months, SRDX's revenue has gone down $2,143,000.
Its 5 year revenue growth rate is now at 40.96%. SRDX's price/earnings ratio has moved down 120.7 over the prior 243 months.īelow are key valuation metrics over time for SRDX.SRDX's price/earnings ratio is -37.2 this is 271.03% lower than that of the median Healthcare stock.
And to visit SURMODICS INC's official web site, go to SRDX Valuation Summary If you're looking for stocks that are quantitatively similar to SURMODICS INC, a group of peers worth examining would be OVID, TDUP, KOPN, HCWB, and LUMO.As for revenue growth, note that SRDX's revenue has grown -5.57% over the past 12 months that beats the revenue growth of merely 16.18% of US companies in our set.Over the past twelve months, SRDX has reported earnings growth of -411.8%, putting it ahead of just 4.47% of US stocks in our set.For SRDX, its debt to operating expenses ratio is greater than that reported by just 15.4% of US equities we're observing.SRDX ranks lowest in Growth there it ranks in the 12th percentile.SRDX's strongest trending metric is Quality it's been moving down over the last 179 days.SRDX scores best on the Stability dimension, with a Stability rank ahead of 80.02% of US stocks.
0 kommentar(er)
